# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jackie Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML037-SYN-TD
- Date: 1971-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marcus Delacroix-Hale, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Three-month review: A1c, urine albumin, lipids, eyes after laser treatment, heart, legs, grief, and a GLP-1 receptor agonist. **S**

## History of present illness

Mr. Robinson returns three months after his first visit. He had the third injections in both eyes a month ago and laser treatment to the right eye nearly three weeks ago. Dr. Ostrowski-Lane reports that the blood has largely cleared, the new vessels are regressing, the macular swelling is much less (central subfield 318 microns right and 334 left at the last scan), and his acuity has improved to 52 letters right and 68 left; she judges the retina stable enough to start a GLP-1 receptor agonist at a low dose with monthly review. The low-vision visit gave him magnifiers and better lighting. He walks two and a half blocks before calf pain in the exercise program. No chest pain. No low blood sugar. His PSA, HIV and hepatitis C tests were normal. He says the counseling helps and he sleeps better, though the loss is with him every day. **S**

| Element | Detail |
|---|---|
| Eyes | Three injections both eyes and laser right eye; acuity 52 and 68 letters |
| Walking | Two and a half blocks |
| Screening | PSA, HIV and hepatitis C normal |
| Mood | PHQ-9 6 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Vision clearer; reads large print with a magnifier |
| Cardiovascular | Positive | Calf pain after two and a half blocks; no chest pain |
| Endocrine | Negative | No low blood sugar |
| Gastrointestinal | Negative | No nausea or change in bowel habit |
| Psychiatric | Positive | Grieving; sleeping better |

5 systems reviewed. **S**

## Current medications

- Metformin 1,000 mg oral tablet, one tablet twice daily with meals **S**
- Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70 **S**
- Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake) **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutes **S**
- Metoprolol succinate extended-release 25 mg oral tablet, one tablet daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one under the tongue for chest pain, repeated every five minutes up to three; call 911 if pain is not better five minutes after the first **S**
- Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**
- Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparation **S**
- Ezetimibe 10 mg oral tablet, one tablet daily **S**
- Dulaglutide 0.75 mg/0.5 mL pen, one injection under the skin once a week; dose to rise to 1.5 mg after at least four weeks only if the retina remains stable **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/76 mmHg; pulse 60 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 101.4 kg; BMI 31.3 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 9.2% (high); Urine albumin-to-creatinine ratio: 54 mg/g (high); Sodium: 139 mmol/L; Potassium: 4.7 mmol/L; Creatinine: 1.18 mg/dL; eGFR (CKD-EPI 1966, race-free): 74 mL/min/1.73 m² (low); Total cholesterol: 150 mg/dL; LDL cholesterol: 74 mg/dL; HDL cholesterol: 40 mg/dL; Triglycerides: 180 mg/dL (high); ALT: 30 U/L; PHQ-9: 6. All results are synthetic.

## Change since baseline

- Hemoglobin A1c: 10.4% (high) at baseline, 9.2% (high) at this visit **S**
- Urine albumin-to-creatinine ratio: 86 mg/g (high) at baseline, 54 mg/g (high) at this visit **S**
- Sodium: 137 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.6 mmol/L at baseline, 4.7 mmol/L at this visit **S**
- Creatinine: 1.12 mg/dL at baseline, 1.18 mg/dL at this visit **S**
- eGFR (CKD-EPI 1966, race-free): 79 mL/min/1.73 m² (low) at baseline, 74 mL/min/1.73 m² (low) at this visit **S**
- Total cholesterol: 226 mg/dL (high) at baseline, 150 mg/dL at this visit **S**
- LDL cholesterol: 142 mg/dL (high) at baseline, 74 mg/dL at this visit **S**
- HDL cholesterol: 38 mg/dL (low) at baseline, 40 mg/dL at this visit **S**
- Triglycerides: 230 mg/dL (high) at baseline, 180 mg/dL (high) at this visit **S**
- ALT: 28 U/L at baseline, 30 U/L at this visit **S**
- PHQ-9: 9 at baseline, 6 at this visit **S**

## Immunizations given today

- COVID-19 vaccine, mRNA, this season **S**
- Hepatitis B vaccine (HepB-CpG), dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/76, pulse 60; weight 101.4 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Feet | Heel healed; no new breaks; fitted shoes |
| Psychiatric | Composed; no thoughts of self-harm |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes** (E11.65). A1c 9.2% from 10.4%: the steady fall planned, without low blood sugar. With the retina stable, a GLP-1 receptor agonist adds cardiovascular protection and glucose lowering. **S**
   - Dulaglutide 0.75 mg weekly, rising to 1.5 mg after four weeks only if the retina stays stable at the monthly review.
   - Reduce glargine by 4 units if fasting readings fall below 100 mg/dL.
   - A1c in three months.
2. **Proliferative diabetic retinopathy with macular edema** (E11.3513). Responding: hemorrhage largely cleared, new vessels regressing, macular swelling much less. **S**
   - Retina clinic monthly, with injections extended as the swelling allows and laser to the left eye if new vessels persist.
3. **Hyperlipidemia** (E78.5). LDL 74 mg/dL from 142 on atorvastatin 80 mg: better, still above the goal below 55 with his stroke, coronary and leg artery disease. ALT 30 U/L. **S**
   - Add ezetimibe 10 mg.
   - Lipids in four to eight weeks, booked today.
4. **Diabetic kidney disease with albuminuria** (E11.22). Urine albumin-to-creatinine ratio 54 mg/g from 86, a fall of 37%; potassium 4.7 mmol/L; creatinine 1.18 mg/dL, eGFR 74. **S**
   - Continue lisinopril 40 mg and empagliflozin.
   - Urine albumin and kidney function in six months.
5. **Bereavement** (Z63.4). PHQ-9 6 from 9; grief continuing, with support. **S**
   - Continue counseling; PHQ-9 again in six months or sooner if he wishes.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 126/76 |
| Examination | Weight and BMI | Every visit | Completed today | 101.4 kg, down 2.6 kg |
| Laboratory | Hemoglobin A1c | Every 3 months while not at goal or after a change | Completed today | 9.2%, from 10.4% |
| Laboratory | Urine albumin-to-creatinine ratio | Three to six months after a treatment change; then 1 to 4 times a year by risk | Completed today | 54 mg/g, from 86 |
| Laboratory | Potassium, creatinine and eGFR | Two to four weeks after starting or increasing an ACE inhibitor or SGLT2 inhibitor; then every 6 to 12 months | Completed today | Sodium 139, potassium 4.7 mmol/L; creatinine 1.18 mg/dL; eGFR 74 |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing a statin; then yearly | Deferred | Late: the panel due 4 to 12 weeks after the atorvastatin increase was not ordered at the four-week visit and was drawn today, at thirteen weeks. No harm: LDL 74 mg/dL, total cholesterol 150, HDL 40, triglycerides 180 mg/dL; ALT 30 U/L. Corrective action: follow-up lipids for today's ezetimibe booked before he left, at four to eight weeks |
| Imaging | Retina care: acuity, OCT, injections and laser | Monthly at the retina clinic while treating | Completed today | Retina report reviewed: third injections and right-eye laser done; central subfield 318 and 334 microns; acuity 52 and 68 letters; monthly review continues |
| Medication safety | Retinopathy safety with a GLP-1 receptor agonist | Retina review within a month of starting and before each dose increase | Completed today | Started only with the retina specialist's agreement; lowest dose; monthly review booked |
| Imaging | Ankle-brachial index | At diagnosis of peripheral artery disease; then with any change in symptoms or a wound | Not indicated | No change in symptoms and no wound; repeat only if symptoms change |
| Examination | Foot inspection; comprehensive foot examination | Every visit with loss of sensation; comprehensive examination yearly | Completed today | Heel healed; no new breaks |
| Examination | Angina review | Every visit | Completed today | No angina on metoprolol |
| Survey | Depression screen (PHQ-9) | At intake and at three months while grieving; at least yearly | Completed today | PHQ-9 6, item 9 scored 0 |
| Laboratory | Vitamin B12 on metformin | Periodically on long-term metformin | Up to date | 380 pg/mL at intake |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infection, dizziness, cost | Every visit | Completed today | No low blood sugar; sick-day rules reviewed for the colonoscopy preparation |
| Medication safety | COVID-19 and hepatitis B vaccines | COVID-19 each autumn; hepatitis B for adults with diabetes under 60 | Completed today | Both given; hepatitis B dose 2 in one month; zoster dose 2 due |
| Self-management | Low-vision services and diabetes tools he can use | When vision limits daily life | Completed today | Low-vision evaluation done: magnifiers, lighting and voice tools |

## Goal progress

- Vision kept or improved: proliferative disease regressed and macular edema reduced on anti-VEGF injections and laser. Outcome by 1971-10-26: Hemorrhage clearing, new vessels regressing after three injections and laser to the right eye; macular thickness down in both eyes; acuity improved. **S**
- A1c falling by about one point every three months without low blood sugar, to below 8% within six months and then below 7%. Outcome by 1971-10-26: 10.4% to 9.2% at three months; no low blood sugar. **S**
- Blood pressure below 130/80 mmHg. Outcome by 1971-10-26: 126/76 in the clinic. **S**
- LDL cholesterol below 55 mg/dL. Outcome by 1971-10-26: 142 to 74 mg/dL on atorvastatin 80 mg; ezetimibe added. **S**
- Walk at least three blocks without stopping, through supervised exercise. Outcome by 1971-10-26: From one block to two and a half blocks. **S**
- Feet kept intact: daily foot checks he can do with low vision, protective footwear, and prompt care for any skin break. Outcome by 1971-10-26: A heel blister found early, healed in five weeks; footwear provided. **S**
- Grief acknowledged and supported, with depression screening repeated. Outcome by 1971-10-26: Meeting the health center's grief counselor; PHQ-9 9 to 6. **S**

## Medication changes

- Started: Ezetimibe 10 mg oral tablet, one tablet daily **S**
- Started: Dulaglutide 0.75 mg/0.5 mL pen, one injection under the skin once a week; dose to rise to 1.5 mg after at least four weeks only if the retina remains stable **S**

## Guideline basis

- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Diabetic Retinopathy Preferred Practice Pattern (2025), American Academy of Ophthalmology (Ophthalmology 2025; Lim JI, et al.)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (2016), New England Journal of Medicine (Marso SP, et al.)
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024), American College of Cardiology and American Heart Association (Circulation 2024)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
- Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023), International Working Group on the Diabetic Foot (Diabetes Metab Res Rev 2024)

## Follow-up

- Retina clinic monthly. Lipids in four to eight weeks. Hepatitis B dose 2 in one month. Colonoscopy next month with the written preparation plan. Review in three months with the A1c. Call for nausea or vomiting that stops him drinking, any change in vision, chest pain, or a skin break on the feet. **S**

